India, Aug. 11 -- San Francisco-based biotech startup Tahoe Therapeutics announced has secured $30 million in fresh funding to accelerate development of its AI-powered virtual cell models, a technology aimed at transforming drug discovery.
The round led by Amplify Partners with participation from Databricks Ventures, General Catalyst, Mubadala Ventures, and others-brings Tahoe's total funding to $42 million and values the company at $120 million.
Founded in 2022 by CEO Nima Alidoust, CSO Johnny Yu, and UCSF scientists Hani Goodarzi and Kevin Shokat, Tahoe is pursuing one of biology's most ambitious goals: digitally recreating the complexity of a living cell.
While AI has made significant advances in protein modeling, building accurate ce...